Hydrochloric Acid

Hydrochloric Acid

SCHEMBL130714

C=CC(=O)OCCN(C)C.Cl

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.52
CHRM4 known ✓ P08173 1/20 0.52
CHRM5 known ✓ P08912 1/20 0.52
CHRM1 known ✓ P11229 1/20 0.52
CHRM3 known ✓ P20309 1/20 0.52
CA2 known ✓ P00918 1/20 0.41
GAA known ✓ P10253 1/20 0.39
TSHR P16473 6/20 0.54
ALDH1A1 P00352 6/20 0.54
TP53 P04637 3/20 0.54
HIF1A Q16665 3/20 0.54
CYP3A4 P08684 2/20 0.54
HSD17B10 Q99714 1/20 0.54
HPGD P15428 1/20 0.53
CHRNB2 P17787 1/20 0.52
CHRNA4 P43681 1/20 0.52
THRB P10828 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
DNM1 Q05193 1/20 0.42
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27625043 0.98 TSHR (0.52) TSHRALDH1A1TP53HIF1ACYP3A4
Hydrochloric Acid SCHEMBL28216348 0.98 TSHR (0.52) TSHRALDH1A1TP53HIF1ACYP3A4
Trimethylammonium SCHEMBL29043998 0.98 TSHR (0.52) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL15115 0.98 TSHR (0.56) TSHRALDH1A1TP53HIF1ACYP3A4
Methylamine SCHEMBL18250065 0.96 TSHR (0.50) TSHRALDH1A1TP53HIF1ACYP3A4
Ethylene SCHEMBL8397415 0.96 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
Ammonia Solution, Strong SCHEMBL1399858 0.96 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
Iodide SCHEMBL1254059 0.96 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL28612529 0.96 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
Fluoride SCHEMBL1255037 0.96 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 907 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739418-A2 ONE-PASS DEOXYGENATION METHOD FOR POLYACRYLAMIDE PRODUCTION KEMIRA OYJ (FI) 2026-05-13 EP claimed
EP-4728136-A1 STRENGTH SYNERGY BETWEEN POLYMER AND PAPERMAKING STRENGTH AID Ecolab USA, Inc. (US) 2026-04-22 EP claimed
EP-4716777-A2 USE OF AMPHOTERIC EMULSION POLYMERS WITH STRENGTH RESINS AS RETENTION AND DRAINAGE AIDS KEMIRA OYJ (FI) 2026-04-01 EP claimed
US-12553188-B2 GPAM compositions and methods KEMIRA OYJ (FI) 2026-02-17 US claimed
EP-4683950-A1 DUAL EMULSIFICATION OF ALKENYL SUCCINIC ANHYDRIDE TO IMPROVE SIZING PERFORMANCE AND STABILITY KEMIRA OYJ (FI) 2026-01-28 EP claimed
US-20250215649-A1 HIGH MOLECULAR WEIGHT GPAM WITH ANIONIC POLYSACCHARIDE PROMOTER KEMIRA OYJ (FI) 2025-07-03 US claimed
CN-115516031-B GPAM compositions and methods 凯米拉公司 2025-06-17 CN claimed
CN-119931618-A Fluid loss agent and preparation method thereof 中国石油天然气集团有限公司 2025-05-06 CN claimed
US-20250137200-A1 HIGH MOLECULAR WEIGHT GPAM WITH ANIONIC POLYMERIC PROMOTER KEMIRA OYJ (FI) 2025-05-01 US claimed
EP-4256009-B1 OIL-IN-WATER EMULSIONS QUADRISE INT LTD (GB) 2025-04-09 EP claimed
US-20040062791-A1 Ion triggerable, cationic polymers, a method of making same and items using same KIMBERLY-CLARK WORLDWIDE, INC. 2004-04-01 US claimed
US-20040063888-A1 Ion triggerable, cationic polymers, a method of making same and items using same KIMBERLY-CLARK WORLDWIDE, INC. 2004-04-01 US claimed
WO-2004026351-A2 IMPROVED ION TRIGGERABLE, CATIONIC POLYMERS, A METHOD OF MAKING SAME AND ITEMS USING SAME KIMBERLY-CLARK WORLDWIDE, INC. (US) 2004-04-01 WO claimed
WO-2004026354-A1 ION TRIGGERABLE, CATIONIC POLYMERS, A METHOD OF MAKING SAME AND ITEMS USING SAME KIMBERLY-CLARK WORLDWIDE, INC. (US) 2004-04-01 WO claimed
WO-2004026958-A1 IMPROVED ION TRIGGERABLE, CATIONIC POLYMERS, A METHOD OF MAKING SAME AND ITEMS USING SAME KIMBERLY-CLARK WORLDWIDE, INC. (US) 2004-04-01 WO claimed
WO-2004026352-A1 USE AS BINDER OF ION TRIGGERABLE, VINYL-BASED CATIONIC POLYMERS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2004-04-01 WO claimed
US-20040058606-A1 Ion triggerable, cationic polymers, a method of making same and items using same KIMBERLY-CLARK WORLDWIDE, INC. 2004-03-25 US claimed
US-20040055704-A1 Ion triggerable, cationic polymers, a method of making same and items using same KIMBERLY-CLARK WORLDWIDE, INC. 2004-03-25 US claimed
EP-0139588-B1 AMPHOLYTIC CATIONIC TETRAPOLYMERS, THEIR USE IN THE TREATMENT OF KERATIN FIBRES AND COMPOSITIONS CONTAINING THEM SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) 1987-07-01 EP claimed
US-4590249-A ACRYLAMIDE, 2-ACRYLAMIDO-2METHYL PROPANE SULFONIC ACID, AMINE SUBSTITUTED UNSATURATED ESTER OR AMIDE AND QUATERNARY AMINE SALT THEREOF SOCIETE FRANCAISE HOECHST (FR) 1986-05-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040062791-A1 Ion triggerable, cationic polymers, a method of making same and items using same PWWP2B, DSG1, WDR1 CHRM2 2205/4885CHRM4 1991/4885CHRM5 2978/4885
US-12553188-B2 GPAM compositions and methods PGM2, SLC6A9, GNMT CHRM2 680/4885CHRM4 1432/4885CHRM5 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.